ERAS-12 A discovery-stage EGFR D2/D3 biparatopic antibody program for EGFR-driven and RAS/MAPK-driven solid tumors that Erasca is evaluating for strategic alternatives.
Visit productCosigns Received
Be the first Cosign
Put your name behind ERAS-12.
Add it to your Products I use list and share why you use it.